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Clinical trials have convincingly demonstrated the efﬁcacy of
implantable cardioverter-deﬁbrillators (ICD) for the pre-
vention of sudden cardiac death in appropriately selected
patients (1–3). As a result, over 140,000 ICD-related pro-
cedures are performed each year in the United States (4).
Despite evidence that deﬁbrillators save lives on a population
level, medical decision making for individual patients can be
difﬁcult. Our limited ability to discern which ICD candi-
dates will derive beneﬁt from their device and which are
most prone to complications contributes to the complexity of
ICD counseling. In addition, the overall cost associated withSee page 788deﬁbrillator implantation has generated an interest in ICD
outcomes that extends far beyond the doctor-patient en-
counter. Ongoing changes in the healthcare landscape,
including provisions fundamental to the Affordable Care
Act, promise heightened emphasis on quality of care and
increased public scrutiny of procedural complications.
In the context of these clinical uncertainties and growing
administrative oversight, multiple studies have attempted to
identify risk factors for ICD complications. A variety of
patient, procedural, and operator characteristics have been
linked to adverse outcomes (5–7), and in 2011, an ICD
implantation risk score was published using data from the
NCDR (National Cardiovascular Data Registry) ICD
Registry (8). This previous model included 10 variables
independently associated with inpatient complications and
provided the implanting physician with a metric to gauge
procedural risk. In this issue of the Journal, Dodson et al. (9)
present a second clinical risk score using more contemporary
data to predict the likelihood of inpatient complication or
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standard NCDR ICD registry forms to derive a score that
can be used to quantify procedural risk. To enhance clinical
relevance, a simpler 12 variable model is also presented.
The Dodson algorithm has several strengths. First, the
investigators used real-world data from the NCDR ICD
Registry to develop their model. This registry contains
detailed information from over 1,400 centers for each
Medicare-funded primary prevention device procedure (4).
It is also noteworthy that the investigators divided their
cohort into derivation and validation groups and demon-
strated similar model performance in both populations.
Whereas the validation dataset is not “external” and there-
fore does not reveal how well the risk score performs among
patients not enrolled in the NCDR, this methodology
provides reassurance that model performance is not overly
optimistic due to statistical “overﬁtting.”
This clinical risk algorithm has several potential applica-
tions. The most natural use of this score would be to esti-
mate a patient’s likelihood of procedural complication. Such
an application has clear clinical merit, especially because
temporal trends may diminish the accuracy of previously
published data. However, we would caution against the use
of this score to justify withholding ICD treatment, as it is
possible that patients at greatest risk for an acute procedural
complication may also derive the most beneﬁt from device
implantation. An analogous phenomenon has recently been
described for atrial ﬁbrillation stroke prophylaxis, whereby
patients at the highest risk of bleeding on anticoagulant
medications (as identiﬁed by the HAS-BLED [Hyperten-
sion, Abnormal liver/renal function, Stroke history or
Bleeding predisposition, Labile international normalized
ratios, “Elderly” (age 65 years), Drugs/alcohol use] score)
also have the greatest risk of thromboembolic events (10). As
a result, these high-risk patients actually derive the greatest
absolute beneﬁt from anticoagulation. Because several of the
covariates in the clinical risk algorithm for ICD complica-
tions may be associated with a greater likelihood of ICD
beneﬁt (such as increased New York Heart Association class
or a history of a cardiac arrest), this score should not be used
in isolation to dissuade ICD implantation. In addition, it
remains unclear how individual patients and physicians
conceptualize absolute risk percentages and use these
numbers for clinical decision making. For instance, the in-
vestigators chose to classify patients with a risk score 30
(absolute risk 4.2%) as “high risk.” Is it reasonable to counsel
an ICD candidate that they are high risk for device im-
plantation when the likelihood of an aggregate complication
is less than 1 in 20, when the complication may be fairly
minor, and when the therapy has mortality beneﬁt?
A second application is to standardize complication rates
across healthcare settings by adjusting for the risk score. By
leveling the playing ﬁeld, physicians and hospitals could
then compare adverse event frequencies in a more equitable
fashion. The investigators present risk-standardized com-
plication rates to illustrate how their score could be used to
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798benchmark hospital performance. Whereas these ﬁndings
may provide reassurance that most centers deliver fairly
comparable implantation results, it could be argued that a
metric that only identiﬁes 3.8% of hospitals as under-
performing may not sufﬁciently bolster efforts to lower ICD
complications. Moreover, whether the current risk score
classiﬁes hospital performance more appropriately than
crude adverse event rates remains untested. Finally, although
many hospitals contribute data to the NCDR for all ICD
implantations, the feasibility of collecting and reporting
similar data for the remainder of device procedures needs
additional exploration. Other possible uses of the risk score,
including identifying patients who can be discharged with
limited post-operative observation, remain speculative and
require further study.
The investigators have appropriately acknowledged the
major limitations of their ICD risk score. Because of the
data source, the model is limited to inpatient complications
and relies on the accuracy of the data supplied by the
implanting hospitals. In addition, even the parsimonious
model lacks clinical convenience and may prove too un-
wieldy for immediate, “on the ﬂy” calculations at the bedside
or in a busy clinic. However, as the investigators point out,
widespread adoption of electronic medical records and
mobile technologies may render their risk score more
accessible to the clinician.
The current investigation has also identiﬁed several speciﬁc
ﬁndings that should inﬂuence clinical practice. Dual chamber
ICDs, compared with single-chamber devices, are again
associated with increased implantation risk (5), and operators
should carefully weigh the decision to implant a dual-
chamber deﬁbrillator in a primary prevention patient without
a pacing indication. It is also noteworthy that hematoma and
pneumothorax are among the most common complications.
When anticoagulation is required, implanting physicians
should consider recent data demonstrating reduced pocket
hematomas when certain device-related procedures are
performed on uninterrupted warfarin (11). In addition,
implanting physicians should be comfortable with techniques
that may minimize the risk of lung injury, including
extrathoracic axillary vein access or cephalic cutdown. Finally,
the investigators have shown that device implantation
during a nonelective admission is a strong risk factor for
periprocedural complication. It should be remembered that
primary prevention ICD implantation is an elective
procedure that, in the absence of other urgent indications
(such as the need for permanent pacing), should be deferred
to the outpatient setting after medical optimization.
In light of their carefully constructed and well-performing
risk model, Dodson et al. (9) should be applauded foradvancing our understanding of ICD procedural outcomes.
Device implantation is a calculated risk taken by a patient
who wishes to trade the acute risk of implantation compli-
cation for chronic protection against arrhythmic death. The
current effort better informs this decision and promises to
play an important role in future attempts to evaluate
physician and hospital performance.
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